- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
YD Bio Limited (Nasdaq: YDES) reports unaudited financial results for the six months ended June 30, 2026: net revenue up 315% to $846,501, swinging from a $1.9 million net loss to $6.7 million net income. Read the full YDES earnings breakdown now.
YD Bio Limited（Nasdaq: YDES）公布2026年上半年未經審計財務業績：淨收入年增315%達846,501美元，並由去年同期淨損191.7萬美元轉為淨利670萬美元。了解YDES最新財報重點、營收結構與下半年展望，立即閱讀完整分析。
YD Bio 與台灣慢性病照護協會、未來健康研究院及台北醫學大學附設醫院醫師共同發表同行評審文章，探索 Omega-3、維生素 D3 與 K2 調節心腦骨軸的整合性框架，已在 Nutrients（MDPI）開放取用。
YD Bio Publishes Heart-Brain-Bone Axis Research in Nutrients — Omega-3, Vitamin D3 & K2
YD Bio 日間「黃金三角」配方與夜間鋅鈣複合配方，由本公司與台灣慢性病照護協會（CDHA）及未來健康研究院（FHI）共同開發。兩款時間營養學配方以 YD Bio 品牌在台灣上市。
YD Bio daytime "Golden Triangle" formula and nighttime zinc-plus-calcium formula, co-developed with the Taiwan Chronic Disease Healthcare Association (CDHA) and the Future Health Institute (FHI). Two chrono-nutrition formulations launched under the YD Bio brand in Taiwan.
YD Bio and Taipei Medical University publish exosome study for keratoconus in international journal Bioengineering — New Research. International Journal. Published. (Nasdaq: YDES)
YD Bio 攜手台北醫學大學研究人員，在國際期刊《生物工程》發表圓錐角膜 LSC 外泌體計算研究，以可重現的數據驅動框架提名 COL1A1、FN1 等分子候選物，為未來再生療法開發奠定基礎。
YD Bio Launches Cross-Border Cancer Testing Pilot in Canada.
YD Bio 與 Numia Health 跨境加拿大啟動癌症檢測服務試辦計畫
